Pentedrone

From Wikipedia, the free encyclopedia

Jump to: navigation, search
Pentedrone
Pentedrone.svg
Systematic (IUPAC) name
(±)-1-phenyl-2-(methylamino)pentan-1-one
Clinical data
Legal status
Legal status
Identifiers
CAS Number 879722-57-3 N
ATC code none
PubChem CID 71750191
ChemSpider 26286729 YesY
UNII 2ELU1B757Q YesY
Chemical data
Formula C12H17NO
Molar mass 191.269 g/mol
 NYesY (what is this?)  (verify)

Pentedrone (also known as α-methylamino-valerophenone) is a stimulant of the cathinone class that has been sold as a designer drug and has been found since 2010 as an ingredient in a number of "bath salt" mixes sold as legal highs.[1][2][3][4][5][6][7]

Pharmacology[edit]

Pentedrone acts as a norepinephrine-dopamine reuptake inhibitor without causing their release, the same mechanism of action as methylphenidate.[8][9]

Side effects[edit]

Pentedrone has been linked to at least one death where it was combined with α-PVP and caused heart failure.[10]

Detection[edit]

A forensic standard of Pentedrone is available, and the compound has been posted on the Forendex website of potential drugs of abuse.[11]

Legal status[edit]

On January 28, 2014, the DEA listed it, along with 9 other synthetic cathinones, on the Schedule 1 with a temporary ban, effective February 27, 2014.[12]

Pentedrone is a Anlage II controlled drug in Germany.

As of October 2015 Pentedrone is a controlled substance in China.[13]

Pentedrone is banned in the Czech Republic.[14]

See also[edit]

References[edit]

  1. ^ EMCDDA Annual Report 2010
  2. ^ Research on Head Shop drugs in Dublin: Part 2
  3. ^ An overview of new psychoactive substances and the outlets supplying them
  4. ^ Folker Westphall, Thomas Junge, Ulrich Girreser, Wolfgang Greibl, Carmen Doering (April 2012). "Mass, NMR and IR spectroscopic characterization of pentedrone and pentylone and identification of their isocathinone by-products". Forensic Science International 217 (1-3): 157–167. doi:10.1016/j.forsciint.2011.10.045. PMID 22115724. 
  5. ^ Chad R. Maheux, Catherine R. Copeland (January 2012). "Chemical analysis of two new designer drugs: buphedrone and pentedrone". Drug Testing and Analysis 4 (1): 17–23. doi:10.1002/dta.385. PMID 22113925. 
  6. ^ Justin L. Poklis, Carl E. Wolf, Omar I. ElJordi, Kai Liu, Shijun Zhang, Alphonse Poklis (January 2015). "Analysis of the First- and Second-Generation Raving Dragon Novelty Bath Salts Containing Methylone and Pentedrone". Journal of Forensic Sciences 60 (11): 234–240. doi:10.1111/1556-4029.12629. PMID 25470207. 
  7. ^ Victor M.R. Zancajo, J. Brito, Marta P. Carrasco, M.R. Bronze, Rui Moreira, Alvaro Lopes (November 2014). "Analytical profiles of "legal highs" containing cathinones available in the area of Lisbon, Portugal". Forensic Science International 244: 102–110. doi:10.1016/j.forsciint.2014.08.010. PMID 25240621. 
  8. ^ Simmler, L. D.; Rickli, A.; Hoener, M. C.; Liechti, M. E. (2014). "Monoamine transporter and receptor interaction profiles of a new series of designer cathinones". Neuropharmacology 79: 152–60. doi:10.1016/j.neuropharm.2013.11.008. PMID 24275046. 
  9. ^ Ji-Young Hwang, Jun-Sub Kim, Ji-Hwan Oh, Sa-Ik Hong, Shi-Xun Ma, Yang-Hee Jung, Yong-Hyun Ko, Seok-Yong Lee, Hyoung-Chun Kim, Choon-Gon Jang (August 2015). "The new stimulant designer compound pentedrone exhibits rewarding properties and affects dopaminergic activity". Addiction Biology. doi:10.1111/adb.12299. PMID 26290055. 
  10. ^ Sykutera, M.; Cychowska, M.; Bloch-Boguslawska, E. (March 2015). "A Fatal Case of Pentedrone and -Pyrrolidinovalerophenone Poisoning". Journal of Analytical Toxicology 39 (4): 324–329. doi:10.1093/jat/bkv011. PMID 25737339. 
  11. ^ "Pentedrone". Southern Association of Forensic Scientists. Retrieved 8 September 2015. 
  12. ^ "Temporary Placement of 10 Synthetic Cathinones into Schedule I". 28 January 2014. 
  13. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015. 
  14. ^ "Látky, o které byl doplněn seznam č. 4 psychotropních látek (příloha č. 4 k nařízení vlády č. 463/2013 Sb.)" (PDF) (in Czech). Ministerstvo zdravotnictví.